Blog

• 
• 
• 
• 

A potential new drug for Alzheimer’s disease and schizophrenia developed by Vanderbilt University scientists was administered July 29 to the first volunteer enrolled in a first-in-human phase 1 clinical trial at the Vanderbilt Institute for Clinical and Translational Research.

Animal studies suggest that the compound, a small molecule called VU319, may have potential for reducing memory impairments in brain disorders such as Alzheimer’s disease and schizophrenia.

A technology developed by Vanderbilt Professor John Wikswo and his group has been selected as a Finalist for the 2017 R&D100 Awards. The award honors 100 top innovations of the prior year, as selected by a panel of expert judges, and is in its 55^th year of recognizing great R&D pioneers and their revolutionary technologies.

nPhase, Inc., a next generation cloud technology company that is commercializing the “Research Electronic Data Capture” (REDCap) software developed by the Department of Biomedical Informatics at Vanderbilt University Medical Center, closed on its second round of investment this past week.